Carlyle Said Close to Buying J&J Diagnostics Unit

Private equity investor Carlyle is in exclusive talks to buy Johnson & Johnson's ortho clinical diagnostics unit for around $4 billion, after knocking Blackstone out of the race, financial market reports said shortly before Christmas. A deal was expected to be concluded in the first half of January.

The unit, described as a small player in a market dominated by larger companies such as Roche, Siemens, Abbott and Danaher, manufactures blood-screening equipment and laboratory blood tests as well as tests capable of identifying blood types and screening for viruses such as HIV and hepatitis C.

At the beginning of 2013, Johnson & Johnson had said it was exploring strategic alternatives for business, a process that could take 12-24 months. Blackstone was reportedly bidding in cooperation with Danaher.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.